Oligometastatic breast cancer: A shift from palliative to potentially curative treatment?

Breast Care

Volumn 9, Issue 1, 2014, Pages 7-14

  Di Lascio, Simona ^a,b   Pagani, Olivia ^a,b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

Breast cancer; Multi disciplinary team; Oligometastatic disease; Treatment

Indexed keywords

ADAPTIVE IMMUNITY; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CHEMOEMBOLIZATION; DISTANT METASTASIS; HUMAN; INNATE IMMUNITY; LIVER METASTASIS; LOCAL THERAPY; LONG TERM SURVIVAL; LUNG METASTASIS; MASTECTOMY; METASTASIS; OLIGOMETASTATIC BREAST CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOFREQUENCY ABLATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; BRAIN METASTASIS; BREAST METASTASIS; META ANALYSIS (TOPIC); PARTIAL MASTECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

EID: 84897035523     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000358750     Document Type: Review

References (93)

1. Howlader N, Noone AM, Krapcho M, et al. (eds): SEER cancer statistics review. Bethesda, MD, National Cancer Institute, 1975-2008. seer.cancer.gov/csr/ 1975-2008/.
2. Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
4. Senkus E, Cardoso F, Pagani O: Time for more optimism in metastatic breast cancer? Cancer Treat Rev 2014;40:220-8.
5. Pagani O, Senkus E, Wood W, et al.: International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010;102:456-63.
6. Weichselbaum RR, Hellman S: Oligometastases revisited. Nat Rev Clin Oncol 2011;8:378-82.
7. Gupta GP, Massague J: Cancer metastasis: building a framework. Cell 2006;127:679-95.
8. Willis L, Graham TA, Alarcn T, Alison MR, et al.: What can be learnt about disease progression in breast cancer dormancy from relapse data? PLoS One 2013;8:e62320.
9. Lussier YA, Xing HR, Salama JK, et al.: MicroRNA expression characterizes oligometastasis(es). PLoS One 2011;6:e28650.
10. Niibe Y, Chang JY: Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012;2012:261096.
11. Cardoso F, Costa A, Norton L, et al.: 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-52.
12. Dorn P, Meriwether A, LeMieux M, et al.: Patterns of distant failure and progression in breast cancer: implications for the treatment of oligometastatic disease. Int J Radiat Oncol 2011;81:S643(abstr 2903).
13. Pennant M, Takwoingi Y, Pennant L, et al.: A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 2010;14:1-103.
14. Milano MT, Zhang H, Metcalfe SK, et al.: Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat 2009;115:601-8.
15. Rubin P, Brasacchio R, Katz A: Solitary metastases: illusion versus reality. Semin Radiat Oncol 2006;16:120-30.
16. Ruiterkamp J, Voogd AC, Bosscha K, Tjan-Heijnen VC, Ernst MF: Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat 2010;120:9-16.
17. Gnerlich J, Dueker JM, Jeffe DB, et al.: Patient and tumor characteristics associated with primary tumor resection in women with stage IV breast cancer: analysis of 1988-2003 SEER data. Breast J 2008;14:538-42.
18. Le Scodan SR, Stevens D, Brain E, et al.: Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol 2009;27:1375-81.
19. Ali D, Le Scodan R: Treatment of the primary tumor in breast cancer patients with synchronous metastases. Ann Oncol 2011;22:9-16.
20. Danna EA, Sinha P, Gilbert M, et al.: Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004;64:2205-11.
21. Morgan SC, Parker CC: Local treatment of metastatic cancer-killing the seed or disturbing the soil? Nat Rev Clin Oncol 2011;8:504-6.
22. Retsky MW, Demicheli R, Hrushesky WJ, et al.: Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 2008;116:730-41.
23. Babiera GV, Rao R, Feng L, et al.: Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006;13:776-82.
24. Salo M: Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 1992; 36:201-20.
25. Khan SA, Stewart AK, Morrow M: Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132:620-7.
26. Rapiti E, Verkooijen HM, Vlastos G, et al.: Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743-9.
27. Deo SS, Jha D: Role of loco-regional surgery in metastatic breast cancer. J Can Res Ther 2013;9: 181-6.
28. Harris E, Barry M, Kell MR: Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol 2013;20:2828-34.
29. Ruiterkamp J, Ernst MF, van de Poll-Franse LV, et al.: Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol 2009;35:1146-51.
30. Badwe R, Parmar V, Hawaldar R, et al.: Surgical removal of primary tumor and axillary lymphnodes in women with metastatic breast cancer at first presentation: a randomized controlled trial. SABCS 2013;abstr S2-02.
31. Soran A, Ozmen V, Ozbas S, et al.: Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01). SABCS 2013;abstr S2-03.
32. Khan SA: Surgery for the intact primary and stage IV breast cancerlacking robust evidence. Ann Surg Oncol 2013;20:2803-5.
33. Ruiterkamp J, Voogd AC, Tjan-Heijnen VC, et al.: SUBMIT: systemic therapy with or without upfront surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation. BMC Surg 2012;12:5.
34. Dellas K: Does radiotherapy have curative potential in metastatic patients? The concept of local therapy in oligometastatic breast cancer. Breast Care 2011;6:363-8.
35. Tree AC, Khoo VS, Eeles RA, et al.: Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013;14:e28-37.
36. Potters L, Kavanagh B, Galvin JM, et al.: American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326-32.
37. Garcia-Barros M, Paris F, Cordon-Cardo C, et al.: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9.
38. Ben-Josef E, Lawrence TS: Using a bigger hammer: the role of stereotactic body radiotherapy in the management of oligometastases. J Clin Oncol 2009;27:1537-9.
39. Corbin KS, Hellman S, Weichselbaum RR: Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013;31:1384-90.
40. Milano MT, Katz AW, Zhang H, Okunieff P: Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012;83:878-86.
41. Chia SK, Speers CH, Dyachkova Y, et al.: The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110: 973-9.
42. Rahman ZU, Frye DK, Smith TL, et al.: Results and long term follow-up for 1581 patients with metastatic carcinoma treated with standard dose doxorubicin- containing chemotherapy. Cancer 1999;85: 104-11.
43. Van Walsum GA, de Ridder JA, Verhoef C, et al.: Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol 2012;38:910-7.
44. Duan XF, Dong NN, Zhang T, Li Q: The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer. Int J Clin Oncol 2013;18:26-32.
45. Atalya G, Biganzoli L, Renard F, et al.: Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003; 39:2439-49.
46. Chua TC, Saxena A, Liauw W, et al.: Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 2011;47:2282-90.
47. Howlader M, Heaton N, Rela M: Resection of liver metastases from breast cancer: towards a management guideline. Int J Surg 2011;9:285-91.
48. Abbott DE, Brouquet A, Mittendorf EA, et al.: Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 2012;151:710-6.
49. Cho SW, Kitisin K, Buck D, et al.: Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases. Int J Surg Oncol 2010;2010:251621.
50. Camacho LH, Kurzrock R, Cheung A: Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer 2007;109:2190-6.
51. Duan XF, Dong NN, Zhang T, Li Q: Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis. J Cancer Res Clin Oncol 2011;137: 1363-70.
52. Shah DR, Green S, Elliot A, et al.: Current oncologic applications of radiofrequency ablation therapies. J Gastrointest Oncol 2013;5:71-80.
53. Illing R, Gillams A: Radiofrequency ablation in the treatment of breast cancer liver metastases. Clin Oncol (R Coll Radiol) 2010;22:781-4.
54. Ta?i Y, Aksoy E, Ta?k?n HE, et al.: A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver. HPB (Oxford) 2013;15:789-93.
55. Vogl TJ, Farshid P, Naguib NN, Zangos S: Thermal ablation therapies in patients with breast cancer liver metastases: a review. Eur Radiol 2013;23:797-804.
56. Hoffmann RT, Paprottka P, Jakobs TF, et al.: Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). Abdom Imaging 2011;36:671-6.
57. Nichols FC: Pulmonary metastasectomy. Thorac Surg Clin 2012;22:91-9.
58. Rena O, Papalia E, Ruffini E, et al.: The role of surgery in the management of solitary pulmonary nodule in breast cancer patients. Eur J Surg Oncol 2007;33:546-50.
59. Diaz-Canton EA, Valero V, Rahman Z, et al.: Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. Ann Oncol 1998;9:413-8.
60. Friedel G, Pastorino U, Ginsberg RJ, et al.: Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg 2002;22:335-44.
61. Welter S, Jacobs J, Krbek T, et al.: Pulmonary metastases of breast cancer. When is resection indicated? Eur J Cardiothorac Surg 2008;34:1228-34.
62. Meimarakis G, Rüttinger D, Stemmler J, et al.: Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer. Ann Thorac Surg 2013;95:1170-80.
63. Ibrahim T, Mercatali L, Amadori D: A new emergency in oncology: bone metastases in breast cancer patients. Oncol Lett 2013;6:306-10.
64. Husband JE, Padhani AR (eds): Metastatic Bone Tumours: Recommendations for Cross-Sectional Imaging in Cancer Management. London, The Royal College of Radiologists, 2006, pp. 108-10.
65. Solomayer EF, Diel IJ, Meyberg, et al.: Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000;59:271-8.
66. Goldhirsch A, Gelber RD, Castiglione M: Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 1988;6:89-97.
67. Ahn SG, Lee HM, et al.: Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J 2013;54:1168-77.
68. Domchek SM, Younger J, Finkelstein DM, Seiden MV: Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000;89:363-8.
69. Koizumi M, Yoshimoto M, Kasumi F, Ogata E: Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003;14:1234-40.
70. Wedin R 2001, Bauer HC, Rutqvist LE: Surgical treatment for skeletal breast cancer metastases: a population-based study of 641 patients. Cancer 2001;92:257-62.
71. Wegener B, Schlemmer M, Stemmler J, et al.: Analysis of orthopedic surgery of bone metastases in breast cancer patients. BMC Musculoskelet Disord 2012;13:232.
72. Milano MT, Katz AW, Okunieff P: Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol 2010;33:157-63.
73. Yimin Y, Zhiwei R, Wei M, Jha R: Current status of percutaneous vertebroplasty and percutaneous kyphoplasty - a review. Med Sci Monit 2013;19: 826-36.
74. Trumm CG, Jakobs TF, Zech CJ, et al.: CT fluoroscopy- guided percutaneous vertebroplasty for the treatment of osteolytic breast cancer metastases: results in 62 sessions with 86 vertebrae treated. J Vasc Interv Radiol 2008;19:1596-606.
75. Dawood S, Gonzalez-Angulo AM: Progress in the biological understanding and management of breast cancer-associated central nervous system metastases. Oncologist 2013;18:675-84.
76. Lim E, Lin NU: New insights and emerging therapies for breast cancer brain metastases. Oncology 2012;26:652-9, 663.
77. Berghoff A, Bago-Horvath Z, De Vries C, et al.: Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 2012;106: 440-6.
78. Weil RJ, Palmieri DC, Bronder JL, et al.: Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-20.
79. Berghoff AS, Bago-Horvath Z, Ilhan-Mutlu A, et al.: Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Br J Cancer 2012;107:1454-8.
80. Niwi?ska A, Murawska M: New breast cancer recursive partitioning analysis prognostic index in patients with newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 2012;82:2065-71.
81. Anders CK, Deal AM, Miller CR, et al.: The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2011;117:1602-11.
82. Dyer MA, Kelly PJ, Chen YH, et al.: Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol Biol Phys 2012;83:e479-86.
83. Aoyama H, Shirato H, Tago M, et al.: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-91.
84. Kocher M, Soffietti R, Abacioglu U, et al.: Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1 to 3 cerebral metastases: results of the EORTC 22952- 26001 study. J Clin Oncol 2011;29:134-41.
85. Linskey ME, Andrews DW, Asher AL, et al.: The role of stereotactic radiosurgery in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:45-68.
86. Gaspar LE, Mehta MP, Patchell RA, et al.: The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:17-32.
87. Kalkanis SN, Kondziolka D, Gaspar LE, et al.: The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:33-43.
88. Patil CG, Pricola K, Sarmiento JM, et al.: Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev 2012;9: CD006121.
89. Andrews DW, Scott CB, Sperduto PW, et al.: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363: 1665-72.
90. Combs SE, Schulz-Ertner D, et al.: Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther Onkol 2004;180: 590-6.
91. Chargari C, Campana F, Pierga JY, et al.: Wholebrain radiation therapy in breast cancer patients with brain metastases. Nat Rev Clin Oncol 2010;7: 632-40.
92. Caballero JA, Sneed PK, Lamborn KR, et al.: Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:303-9.
93. Kelly PJ, Lin NU, Claus EB, et al.: Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors. Cancer 2012; 118:2014-20.